Investigating the effect of mesenchymal stem cells in patients with muscular dystrophy

Study the effect of intravenous injection of dental pulp mesenchymal stem cells in treatment of patients with Limb-Girdle Muscular Dystrophy (LGMD)- A Phase 1 & 2 Clinical Trial

Status

Recruiting

Phases

Phase 2

Study type

Interventional

Source

IRCT

Registry ID

IRCT20140911019125N13

Enrollment

Registered

2025-03-10

Start date

2025-04-21

Completion date

Unknown

Last updated

2025-07-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Treatment of patients with muscular dystrophy. Disorders of muscle in diseases classified elsewhere

Interventions

Intervention group: In the intervention group, after selecting patients, stem cell samples will be injected intramuscularly at a rate of 40 million per kilogram of body weight. The patients' results w

Eligibility

Sex/Gender

All

Age

18 Years to 95 Years

Inclusion criteria

Inclusion criteria: Age between 18 and 95 years Patients confirmed to have Limb-Girdle Muscular Dystrophy by definitive laboratory methods

Exclusion criteria

Exclusion criteria: Patients undergoing other clinical trials.

Design outcomes

Primary

Measure	Time frame
Clinical symptoms. Timepoint: 14 and 28 days after mesenchymal stem cell injection. Method of measurement: Questionnaire and clinical examination.;Electromyography. Timepoint: 14 and 28 days after mesenchymal stem cell injection. Method of measurement: Check with the device.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactAlireza Farsinejad

Kerman University of Medical Sciences

afarsinejad@kmu.ac.ir+98 34 3132 5374

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026